Skip to main content
    P

    Plus Therapeutics Inc (PSTV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    +0.18 (+23.32%)

    Market Cap: $26.64M

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Plus Therapeutics Inc (PSTV) Earnings: Report Dates and Results

    Updated May 15, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Mar 31, 2026, Plus Therapeutics reported EPS of -$1.05, below the -$0.87 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    53%(20/38)
    Avg Surprise
    +2.86%

    Upcoming Estimates

    Results pendingPeriod ending Sep 30, 2026
    EPS Consensus-$0.86
    Range-$0.92 - -$0.80
    3 analysts
    EPS Revisions
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.81-5.8%
    60d ago$0.00n/a
    30d ago-$0.85-1.2%
    7d ago-$0.860.0%
    Current-$0.86
    Revenue Consensus
    $1.47M
    Range$1.00M - $2.00M
    4 analysts
    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    N/A
    RangeN/A

    Next Report

    PSTV's report for the quarter ended Sep 30, 2026 is not on the earnings calendar yet.

    PSTV Earnings Call

    The latest PSTV earnings call transcript on file is labeled 2024Q3.

    Read the 2024Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, PSTV beat 20, missed 17 and matched 3. Revenue for the quarter ended Mar 31, 2026 was $1.03M, down 2.8% from $1.06M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Mar 31, 2026-$1.05-$0.87-$1.00 - -$0.75-20.69%MissN/A40 up, 2 downMay 15, 2026$1.03M
    Dec 31, 2025-$0.04-$0.04-$0.05 - -$0.03-12.36%MissN/A31 up, 1 downMar 12, 2026$1.37M
    Sep 30, 2025-$1.00-$0.87-$1.00 - -$0.75-14.94%MissN/A20 up, 0 downOct 30, 2025$1.40M
    Jun 30, 2025-$0.16-$0.13-$0.13 - -$0.13-23.08%MissN/A11 up, 0 downAug 14, 2025$1.39M
    Mar 31, 2025-$14.17-$7.33-$13.75 - -$2.25-93.32%MissN/A32 up, 0 downMay 30, 2025$1.06M
    Dec 31, 2024-$0.49-$0.50-$0.58 - -$0.43+1.35%BeatN/A31 up, 2 downMar 27, 2025$1.41M
    Sep 30, 2024-$9.25-$14.06-$19.50 - -$8.75+34.21%BeatN/A41 up, 2 downNov 14, 2024$1.46M
    Jun 30, 2024-$11.25-$13.25-$17.50 - -$9.25+15.09%BeatN/A30 up, 0 downAug 14, 2024$1.28M
    Mar 31, 2024-$18.75-$27.25-$36.50 - -$18.00+31.19%BeatN/A20 up, 0 downMay 15, 2024$1.68M
    Dec 31, 2023-$0.84-$1.07-$1.91 - -$0.77+21.50%BeatN/A40 up, 0 downMar 5, 2024$1.31M
    Sep 30, 2023-$25.00-$29.42-$46.50 - -$14.50+15.02%BeatN/A40 up, 0 downOct 31, 2023$1.24M
    Jun 30, 2023-$14.75-$50.75-$62.00 - -$39.25+70.94%BeatN/A40 up, 0 downAug 14, 2023$1.85M
    Mar 31, 2023-$52.50-$55.00N/A+4.55%BeatN/A30 up, 0 downApr 20, 2023$506000
    Dec 31, 2022-$0.22-$0.12-$0.15 - -$0.10-83.33%MissN/A30 up, 0 downFeb 23, 2023$151000
    Sep 30, 2022-$71.25-$80.00-$82.46 - -$78.71+10.94%BeatN/A20 up, 0 downOct 20, 2022$73000
    Jun 30, 2022-$90.00-$71.25N/A-26.32%MissN/AN/A0 up, 0 downJul 21, 2022N/A
    Mar 31, 2022-$71.25-$71.25N/A0.00%In lineN/A10 up, 0 downApr 21, 2022N/A
    Dec 31, 2021-$0.27-$0.27-$0.27 - -$0.270.00%In lineN/A1N/AFeb 24, 2022N/A
    Sep 30, 2021-$104.77-$91.25-$101.20 - -$78.71-14.82%MissN/A30 up, 0 downOct 21, 2021N/A
    Jun 30, 2021-$93.75-$93.75N/A0.00%In lineN/A2N/AJul 22, 2021N/A
    Mar 31, 2021-$123.75-$146.25-$187.41 - -$104.95+15.38%BeatN/A4N/AApr 22, 2021N/A
    Dec 31, 2020-$0.67-$0.39-$0.55 - -$0.26-71.79%Miss-391.3%4N/AFeb 22, 2021N/A
    Sep 30, 2020-$146.25-$206.25N/A+29.09%BeatN/AN/AN/AOct 22, 2020N/A
    Jun 30, 2020-$0.26-$0.75-$0.75 - -$0.75+65.33%BeatN/A1N/AAug 10, 2020N/A
    Mar 31, 2020-$266.14-$281.25N/A+5.37%BeatN/A1N/AMay 14, 2020N/A
    Dec 31, 2019$0.23-$0.66N/A+134.85%BeatN/AN/AN/AMar 30, 2020$1.19M
    Sep 30, 2019-$11.25-$2,193.75N/A+99.49%BeatN/AN/AN/ANov 14, 2019N/A
    Jun 30, 2019-$1,920.00-$3,750.00N/A+48.80%BeatN/AN/AN/AAug 15, 2019N/A
    Mar 31, 2019-$3,375.00-$3,656.25N/A+7.69%BeatN/AN/AN/AMay 14, 2019N/A
    Dec 31, 2018-$8.05-$14.67N/A+45.13%BeatN/AN/AN/AMar 29, 2019N/A
    Sep 30, 2018-$10,312.49-$4,500.00N/A-129.17%MissN/AN/AN/ANov 14, 2018N/A
    Jun 30, 2018-$11,062.49-$8,925.00N/A-23.95%MissN/AN/AN/AAug 14, 2018N/A
    Mar 31, 2018-$13,124.99-$10,000.00N/A-31.25%MissN/AN/AN/AMay 10, 2018$731000
    Dec 31, 2017-$50.00-$42.50N/A-17.65%MissN/AN/AN/AMar 8, 2018$662000
    Sep 30, 2017-$26,249.99-$29,374.99N/A+10.64%BeatN/AN/AN/ANov 9, 2017$467000
    Jun 30, 2017-$35,624.98-$33,749.98N/A-5.56%MissN/AN/AN/AAug 10, 2017$969000
    Mar 31, 2017-$48,749.98-$57,187.47N/A+14.75%BeatN/AN/AN/AMay 11, 2017$591000
    Dec 31, 2016-$120.00-$115.00N/A-4.35%MissN/AN/AN/AMar 23, 2017$1.47M
    Sep 30, 2016-$48,749.98-$44,999.98N/A-8.33%MissN/AN/AN/ANov 9, 2016$731000
    Jun 30, 2016-$80,624.96-$73,125.27N/A-10.26%MissN/AN/AN/AAug 4, 2016$1.13M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$15.37, after -$39.74 the year before. It was -$213,869.89 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$15.37N/A
    Dec 31, 2024-$39.74N/A
    Dec 31, 2023-$93.09N/A
    Dec 31, 2022-$232.72N/A
    Dec 31, 2021-$322.54N/A
    Dec 31, 2020-$413.32N/A
    Dec 31, 2019-$5,306.02N/A
    Dec 31, 2018-$34,508.02N/A
    Dec 31, 2017-$110,674.95N/A
    Dec 31, 2016-$213,869.89N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2024Q3 for the period ended Sep 30, 2024, runs about 4,900 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q3Sep 30, 20244,8726
    2024Q2Jun 30, 20244,7226

    2024Q3 Earnings Call

    Opening remarks

    Marc Hedrick President and CEO Thank you, Sheri. Good afternoon, everybody, and thank you once again for taking the time to join us today as we provide an overview of recent business highlights and discuss our third quarter 2024 financial results. Joining me for the call today is Mr. Andrew Sims, our Chief Financial Officer. I'll begin the call by reviewing our recent clinical and corporate progress in the third quarter and then turn the call over to Andrew for a review of our financials, and then we'll both come back for Q&A. I'll begin this afternoon with an overview of our leptomeningeal metastases program in which we are investigating our lead radiotherapeutic Rhenium (186Re) Obisbemeda in ReSPECT-LM trial. As a note, going forward for this call, I'll refer to Rhenium (186Re) Obisbemeda as RNL, which is its research name for the sake of brevity. Part one of our development program, our ongoing ReSPECT-LM Phase 1 single-administration, dose-escalation trial, is perhaps closing in on a maximal dose of 5 in which we administer a very substantial dose of RNL approximately 66 millicuries. The Data Safety and Monitoring Board recommended proceeding to a modified lesser cohort 6 dose of 75 millicuries, and the first patient has been treated. To date, 21 patients have participated, including a subset of three patients who responded well to the initial dose and have received multiple doses under compassionate use. Part two of our integrated development plan is to expand the Phase 1 ReSPECT-LM trial to a multiple dose administration trial. Relatedly, in Q3, we reached agreement with the FDA to proceed under a multiple dose escalation protocol, and we are currently in the site start-up phase for that trial. I'll review that trial design more fully in a moment. In terms of clinical data from the ReSPECT-LM single administration trial, we presented an interim update at the SNO/ASCO conference in August through cohorts 1 through 4. Here are the key highlights from that presentation. Doses of RNL up to 44 millicuries were found to be safe and well tolerated with no dose-limiting toxicities. Pharmacokinetic data demonstrated a very high therapeutic index, specifically about a 50 to 100 target to off-target ratio through cohorts 1 through 3, meaning circulating tumor cells were reduced on average 53% at day 28 post-treatment. The median overall survival for cohorts 1 through 4 was 12 months, which is quite favorable compared to the historically reported consensus of approximately four months with treatment in breast and non-small cell lung cancer. The full presentation from that meeting is available on our website.

    Frequently Asked Questions About PSTV

    Did PSTV beat earnings estimates last quarter?

    No. Plus Therapeutics reported EPS of -$1.05 for the quarter ended Mar 31, 2026, below the -$0.87 estimate by 20.69%.

    What EPS do analysts expect from PSTV next quarter?

    The consensus EPS estimate for Plus Therapeutics for the quarter ended Sep 30, 2026 is -$0.86 from 3 analysts, with estimates from -$0.92 to -$0.80.

    How often does PSTV beat earnings estimates?

    Plus Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -14.22%.